Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer
Therapeutic Advances in Medical Oncology
Published online on March 19, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Rectal cancer recurrence remains a major therapeutic challenge, particularly in patients unresponsive to conventional regimens. Tumors with mismatch-repair-proficient (pMMR) or microsatellite-stable (MSS) status represent the majority of colorectal ...
Rectal cancer recurrence remains a major therapeutic challenge, particularly in patients unresponsive to conventional regimens. Tumors with mismatch-repair-proficient (pMMR) or microsatellite-stable (MSS) status represent the majority of colorectal ...